Lazard Asset Management LLC Editas Medicine, Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

A detailed history of Lazard Asset Management LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 76 shares of EDIT stock, worth $202. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 204 62.75%

Holding current value

$202

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $433 - $762	-128 Reduced 62.75%	76 $0
Q2 2024 Aug 14, 2024	SELL	$4.67 - $7.28 $13,402 - $20,893	-2,870 Reduced 93.36%	204 $0
Q1 2024 May 14, 2024	SELL	$7.03 - $11.07 $11,993 - $18,885	-1,706 Reduced 35.69%	3,074 $22,000
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $1,156 - $2,055	185 Added 4.03%	4,780 $48,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $14,269 - $19,197	2,062 Added 81.41%	4,595 $35,000
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $343 - $619	-54 Reduced 2.09%	2,533 $20,000
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $20,365 - $33,402	-2,897 Reduced 52.83%	2,587 $18,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $33,845 - $53,738	-4,068 Reduced 42.59%	5,484 $48,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $10,615 - $16,953	873 Added 10.06%	9,552 $116,000
Q2 2022 Aug 09, 2022	SELL	$9.99 - $21.35 $1.16 Million - $2.48 Million	-116,226 Reduced 93.05%	8,679 $102,000
Q1 2022 May 13, 2022	BUY	$14.08 - $27.63 $482,225 - $946,299	34,249 Added 37.78%	124,905 $2.38 Million
Q4 2021 Feb 09, 2022	BUY	$26.55 - $40.57 $1.24 Million - $1.89 Million	46,587 Added 105.71%	90,656 $2.41 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $81,445 - $151,277	2,074 Added 4.94%	44,069 $1.81 Million
Q2 2021 Aug 12, 2021	BUY	$31.29 - $56.64 $1.29 Million - $2.34 Million	41,345 Added 6360.77%	41,995 $2.38 Million
Q1 2021 May 14, 2021	SELL	$39.71 - $90.58 $97,329 - $222,011	-2,451 Reduced 79.04%	650 $27,000
Q4 2020 Feb 11, 2021	BUY	$27.07 - $84.35 $83,944 - $261,569	3,101 New	3,101 $217,000
Q3 2020 Nov 13, 2020	SELL	$28.06 - $37.16 $2,216 - $2,935	-79 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$18.5 - $34.34 $1,461 - $2,712	79 New	79 $2,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $183M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Editas Medicine, Inc. Transaction History